@article{oai:repo.qst.go.jp:00083459,
 author = {Oba, Takaaki and Makino, Kenichi and Kajihara, Ryutaro and Yokoi, Toshihiro and Araki, Ryoko and Abe, Masumi and Minderman, Hans and E Chang, Alfred and Odunsi, Kunle and Ito, Fumito and Ryoko, Araki and Masumi, Abe},
 issue = {5},
 journal = {Journal for immunotherapy of cancer},
 month = {May},
 note = {Dendritic cells (DCs) are a promising therapeutic target in cancer immunotherapy given their ability to prime antigen-specific T cells, and initiate antitumor immune response. A major obstacle for DC-based immunotherapy is the difficulty to obtain a sufficient number of functional DCs. Theoretically, this limitation can be overcome by using induced pluripotent stem cells (iPSCs); however, therapeutic strategies to engage iPSC-derived DCs (iPSC-DCs) into cancer immunotherapy remain to be elucidated. Accumulating evidence showing that induction of tumor-residing DCs enhances immunomodulatory effect of radiotherapy (RT) prompted us to investigate antitumor efficacy of combining intratumoral administration of iPSC-DCs with local RT.},
 title = {In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.},
 volume = {9},
 year = {2021}
}